ArticleFrontiers in endocrinology2026
Stage-dependent alterations of Sonoclot coagulation profiles across the spectrum of diabetic peripheral neuropathy.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Microvascular hypercoagulability is a primary driver of diabetic peripheral neuropathy (DPN). This study aimed to evaluate comprehensive whole-blood viscoelastic profiles using the Sonoclot analyzer across distinct clinical stages of DPN. Methods: This cross-sectional study consecutively enrolled 289 hospitalized patients with type 2 diabetes mellitus (T2DM). Based on the Toronto Clinical Neuropathy Score (TCNS) and nerve conduction studies, participants were classified into non-DPN, subclinical DPN (sDPN), and confirmed DPN groups. Sonoclot-derived parameters were quantitatively assessed. Multivariable logistic regression, restricted cubic spline (RCS) analysis, and receiver operating characteristic (ROC) curve analysis were performed to evaluate diagnostic performance. Results: Among the 289 participants, 93 (32.2%) were diagnosed with sDPN and 70 (24.2%) with confirmed DPN. CR levels did not differ significantly between the non-DPN and sDPN groups, whereas markedly elevated CR levels were observed in patients with confirmed DPN. After adjustment for age, diabetes duration, HbA1c, BMI, and platelet count, CR remained independently associated with DPN (odds ratio 1.154, 95% CI 1.075-1.239). RCS analysis demonstrated a significant nonlinear association between CR levels and the presence of DPN. ROC analysis identified an optimal CR cutoff value of 31.1 (AUC = 0.729), with a sensitivity of 47.1% and a specificity of 98.9%. The moderate sensitivity suggests limited utility as a standalone screening marker. Conclusion: Sonoclot-derived CR is independently associated with clinically confirmed DPN. Longitudinal studies are required to clarify the temporal nature of this association.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.